EIB and LUMICKS Partner to Accelerate Cancer Drug Discovery with €20 Million Investment in Advanced Immunotherapy Tools

(IN BRIEF) Amsterdam-based LUMICKS has secured €20 million in venture debt from the European Investment Bank (EIB) to advance its next-generation cell avidity platform, which aims to accelerate the development of immunotherapies for cancer treatment. Supported by the InvestEU initiative, … Read the full press release →